Aiden Haghikia

Prof. Aiden Haghikia


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2015 in Immunity
Verified
Journal Article
Closed access
AHAiden Haghikia
Aiden Haghikia
SJStefanie Jörg
Stefanie Jörg
ADAlexander Duscha
Alexander Duscha
JBJohannes Berg
Johannes Berg
AMArndt Manzel
Arndt Manzel
RLRalf Linker
Ralf Linker

1 March 2020 in Cell
Verified
Journal Article
Closed access
ADAlexander Duscha
Alexander Duscha
BGBarbara Gisevius
Barbara Gisevius
SHSarah Hirschberg
Sarah Hirschberg
NYNissan Yissachar
Nissan Yissachar
GSGabriele I. Stangl
Gabriele I. Stangl
AHAiden Haghikia
Aiden Haghikia

19 May 2011 in Molecular Neurodegeneration
Verified
Journal Article
Open access
PDF file
ETElahe Taherzadeh-Fard
Elahe Taherzadeh-Fard
Carsten SaftCarsten Saft
Carsten Saft
DADenis A Akkad
Denis A Akkad
SWStefan Wieczorek
Stefan Wieczorek
AHAiden Haghikia
Aiden Haghikia
LALarissa Arning
Larissa Arning
Background: Huntington disease (HD) is an inherited neurodegenerative disease caused by an abnormal expansion of a CAG repeat in the huntingtin HTT (HD) gene. The primary genetic determinant of the age at onset (AO) is the length of the HTT CAG repeat; however, the remaining genetic contribution to the AO of HD has largely not been elucidated. Recent studies showed that impaired functioning of the peroxisome proliferator-activated receptor gamma coactivator 1a (PGC-1alpha) contributes to mitochondrial dysfunction and appears to play an important role in HD pathogenesis. Further genetic evidence for involvement of PGC-1alpha in HD pathogenesis was generated by the findings that sequence variations in the PPARGC1A gene encoding PGC-1alpha exert modifying effects on the AO in HD. In this study, we hypothesised that polymorphisms in PGC-1alpha downstream targets might also contribute to the variation in the AO. Results: In over 400 German HD patients, polymorphisms in the nuclear respiratory factor 1 gene, NRF-1, and the mitochondrial transcription factor A, encoded by TFAM showed nominally significant association with AO of HD. When combining these results with the previously described modifiers rs7665116 in PPARGC1A and C7028T in the cytochrome c oxidase subunit I (CO1, mt haplogroup H) in a multivariable model, a substantial proportion of the variation in AO can be explained by the joint effect of significant modifiers and their interactions, respectively. Conclusions: These results underscore that impairment of mitochondrial function plays a critical role in the pathogenesis of HD and that upstream transcriptional activators of PGC-1alpha may be useful targets in the treatment of HD.

4 August 2016 in Cellular and Molecular Life Sciences
Verified
Journal Article
Open access
PDF file
SJStefanie Jörg
Stefanie Jörg
DGDiana A. Grohme
Diana A. Grohme
MEMelanie Erzler
Melanie Erzler
MBMarilene Binsfeld
Marilene Binsfeld
AHAiden Haghikia
Aiden Haghikia
MKMarkus KLEINEWIETFELD
Markus KLEINEWIETFELD
An increase in autoimmune diseases poses a socioeconomic challenge worldwide. Predisposing genetic risk has been identified, yet environmental factors make up a significant part of the risk in disease initiation and propagation. Next to improved hygiene and a gross reduction of infections, changes in dietary habits are one of the most evident Western lifestyle factors potentially associated with the increase in autoimmune diseases. Growing evidence suggests that particularly a typical ‘Western diet’, rich in saturated fat and salt and related pathologies can have a profound impact on local and systemic immune responses under physiologic and autoimmune conditions such as in multiple sclerosis (MS). In this review, we discuss recent findings on environmental factors influencing autoimmunity with an emphasis on the impact of ‘Western diet’ on immune homeostasis and gut microbiota in MS.

6 February 2020 in Cells
Verified
Journal Article
Open access
PDF file
THTobias Hegelmaier
Tobias Hegelmaier
MLMarco Lebbing
Marco Lebbing
ADAlexander Duscha
Alexander Duscha
LTLaura Tomaske
Laura Tomaske
Lars TöngesLars Tönges
Lars Tönges
AHAiden Haghikia
Aiden Haghikia
The impact of the gut microbiome is being increasingly appreciated in health and in various chronic diseases, among them neurodegenerative disorders such as Parkinson’s disease (PD). In the pathogenesis of PD, the role of the gut has been previously established. In conjunction with a better understanding of the intestinal microbiome, a link to the misfolding and spread of alpha-synuclein via inflammatory processes within the gut is discussed. In a case-control study, we assessed the gut microbiome of 54 PD patients and 32 healthy controls (HC). Additionally, we tested in this proof-of-concept study whether dietary intervention alone or additional physical colon cleaning may lead to changes of the gut microbiome in PD. 16 PD patients underwent a well-controlled balanced, ovo-lacto vegetarian diet intervention including short fatty acids for 14 days. 10 of those patients received additional treatment with daily fecal enema over 8 days. Stool samples were collected before and after 14 days of intervention. In comparison to HC, we could confirm previously reported PD associated microbiome changes. The UDPRS III significantly improved and the levodopa-equivalent daily dose decreased after vegetarian diet and fecal enema in a one-year follow-up. Additionally, we observed a significant association between the gut microbiome diversity and the UPDRS III and the abundance of Ruminococcaceae. Additionally, the abundance of Clostridiaceae was significantly reduced after enema. Dietary intervention and bowel cleansing may provide an additional non-pharmacologic therapeutic option for PD patients.

Verified
Journal Article
Open access
PDF file
SHSarah Hirschberg
Sarah Hirschberg
BGBarbara Gisevius
Barbara Gisevius
ADAlexander Duscha
Alexander Duscha
AHAiden Haghikia
Aiden Haghikia
Within the last century, human lifestyle and dietary behaviors have changed dramatically. These changes, especially concerning hygiene, have led to a marked decrease in some diseases, i.e., infectious diseases. However, other diseases that can be attributed to the so-called ‘Western’ lifestyle have increased, i.e., metabolic and cardiovascular disorders. More recently, multifactorial disorders, such as autoimmune and neurodegenerative diseases, have been associated with changes in diet and the gut microbiome. In particular, short chain fatty acid (SCFA)-producing bacteria are of high interest. SCFAs are the main metabolites produced by bacteria and are often reduced in a dysbiotic state, causing an inflammatory environment. Based on advanced technologies, high-resolution investigations of the abundance and composition of the commensal microbiome are now possible. These techniques enable the assessment of the relationship between the gut microbiome, its metabolome and gut-associated immune and neuronal cells. While a growing number of studies have shown the indirect impact of gut metabolites, mediated by alterations of immune-mediated mechanisms, the direct influence of these compounds on cells of the central nervous system needs to be further elucidated. For instance, the SCFA propionic acid (PA) increases the amount of intestine-derived regulatory T cells, which furthermore can positively affect the central nervous system (CNS), e.g., by increasing remyelination. However, the question of if and how PA can directly interact with CNS-resident cells is a matter of debate. In this review, we discuss the impact of an altered microbiome composition in relation to various diseases and discuss how the commensal microbiome is shaped, starting from the beginning of human life.